Important Role of Endogenous Erythropoietin System in Recruitment of Endothelial Progenitor Cells in Hypoxia-Induced Pulmonary Hypertension in Mice

Background— Recent studies have suggested that endogenous erythropoietin (Epo) plays an important role in the mobilization of bone marrow–derived endothelial progenitor cells (EPCs). However, it remains to be elucidated whether the Epo system exerts protective effects on pulmonary hypertension (PH), a fatal disorder encountered in cardiovascular medicine. Methods and Results— A mouse model of hypoxia-induced PH was used for study. We evaluated right ventricular systolic pressure, right ventricular hypertrophy, and pulmonary vascular remodeling in mice lacking the Epo receptor (EpoR) in nonerythroid lineages (EpoR−/− rescued mice) after 3 weeks of exposure to hypoxia. Those mice lack EpoR in the cardiovascular system but not in the hematopoietic system. The development of PH and pulmonary vascular remodeling were accelerated in EpoR−/− rescued mice compared with wild-type mice. The mobilization of EPCs and their recruitment to the pulmonary endothelium were significantly impaired in EpoR−/− rescued mice. By contrast, reconstitution of the bone marrow with wild-type bone marrow cells ameliorated PH in the EpoR−/− rescued mice. Hypoxia enhanced the expression of EpoR on pulmonary endothelial cells in wild-type but not EpoR−/− rescued mice. Finally, hypoxia activated endothelial nitric oxide synthase in the lungs in wild-type mice but not in EpoR−/− rescued mice. Conclusions— These results indicate that the endogenous Epo/EpoR system plays an important role in the recruitment of EPCs and prevents the development of PH during chronic hypoxia in mice in vivo, suggesting the therapeutic importance of the system for the treatment of PH.

[1]  C. Heeschen,et al.  Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. , 2003, Blood.

[2]  M. Frid,et al.  Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[3]  S. Masuda,et al.  Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. , 1998, Biochemical and biophysical research communications.

[4]  N. Voelkel,et al.  Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? , 2000, The Journal of clinical investigation.

[5]  J. Loscalzo,et al.  Increased Susceptibility to Pulmonary Hypertension in Heterozygous BMPR2-Mutant Mice , 2005, Circulation.

[6]  G. Wright,et al.  Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia‐reperfusion injury , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  Y. Tabata,et al.  Hybrid Cell–Gene Therapy for Pulmonary Hypertension Based on Phagocytosing Action of Endothelial Progenitor Cells , 2003, Circulation.

[8]  Y. Kagaya,et al.  High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. , 2005, Journal of the American College of Cardiology.

[9]  A. Schechter,et al.  Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. , 2004, Blood.

[10]  M. Maclean,et al.  Contribution of the 5-HT1B Receptor to Hypoxia-Induced Pulmonary Hypertension: Converging Evidence Using 5-HT1B-Receptor Knockout Mice and the 5-HT1B/1D-Receptor Antagonist GR127935 , 2001, Circulation research.

[11]  A. Dusso,et al.  Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. , 1993, Kidney international.

[12]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[13]  Z. Erbayraktar,et al.  Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic , 2004, Science.

[14]  A. Dudley,et al.  A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. , 2005, The Biochemical journal.

[15]  Masayuki Yamamoto,et al.  Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels. , 2003, Blood.

[16]  H. Miller,et al.  Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. , 2005, Cardiovascular research.

[17]  J. Isner,et al.  Estrogen-Mediated, Endothelial Nitric Oxide Synthase–Dependent Mobilization of Bone Marrow–Derived Endothelial Progenitor Cells Contributes to Reendothelialization After Arterial Injury , 2003, Circulation.

[18]  R. Flavell,et al.  Endothelial Cells Require STAT3 for Protection against Endotoxin-induced Inf lammation , 2003, The Journal of experimental medicine.

[19]  Satoru Takahashi,et al.  Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. , 2002, Blood.

[20]  D. Fliser,et al.  Erythropoietin regulates endothelial progenitor cells. , 2004, Blood.

[21]  D. Katayose,et al.  Increased expression of PDGF A- and B-chain genes in rat lungs with hypoxic pulmonary hypertension. , 1993, The American journal of physiology.

[22]  J. Isner,et al.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.

[23]  C. Heeschen,et al.  Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells , 2003, Nature Medicine.

[24]  Rudolf Jaenisch,et al.  Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor , 1995, Cell.

[25]  K. Maiese,et al.  New avenues of exploration for erythropoietin. , 2005, JAMA.

[26]  A. Quyyumi,et al.  Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. , 2003, The New England journal of medicine.

[27]  M. Yamagishi,et al.  C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. , 2004, American journal of respiratory and critical care medicine.

[28]  S. Masuda,et al.  Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. , 2005, The New England journal of medicine.

[29]  F. Luft,et al.  Signal transduction of erythropoietin in endothelial cells. , 1996, Kidney international.

[30]  A. Anagnostou,et al.  Erythropoietin receptor mRNA expression in human endothelial cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  N. Hill,et al.  Exogenous erythropoietin fails to augment hypoxic pulmonary hypertension in rats. , 1993, Respiration physiology.

[32]  J. Isner,et al.  VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.

[33]  L. Ortiz,et al.  Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. , 1999, Circulation research.

[34]  S. Rafii,et al.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.

[35]  R. Johns,et al.  Effects of chronic hypoxia and altered hemodynamics on endothelial nitric oxide synthase expression in the adult rat lung. , 1998, The Journal of clinical investigation.

[36]  T. Peterson,et al.  Paracrine mitogenic effect of human endothelial progenitor cells: role of interleukin-8. , 2005, American journal of physiology. Heart and circulatory physiology.

[37]  P. Huang,et al.  Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. , 1998, The Journal of clinical investigation.

[38]  P. Schmucker,et al.  Altered pulmonary vascular reactivity in mice with excessive erythrocytosis. , 2004, American journal of respiratory and critical care medicine.

[39]  F. Prósper,et al.  Erythropoietin Can Induce the Expression of Bcl-xLthrough Stat5 in Erythropoietin-dependent Progenitor Cell Lines* , 1999, The Journal of Biological Chemistry.

[40]  I. Shapira,et al.  The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. , 2000, Journal of the American College of Cardiology.

[41]  G. Semenza,et al.  A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.

[42]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[43]  Pietro Ghezzi,et al.  Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  T. Murohara,et al.  Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. , 2000, The Journal of clinical investigation.

[45]  S. Dimmeler,et al.  Endothelial Progenitor Cells: Characterization and Role in Vascular Biology , 2004, Circulation research.

[46]  D. Stewart,et al.  Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow–Derived Endothelial-Like Progenitor Cells: Efficacy of Combined Cell and eNOS Gene Therapy in Established Disease , 2005, Circulation research.

[47]  N. Hill,et al.  Pulmonary vascular adaptations to augmented polycythemia during chronic hypoxia. , 1995, Journal of applied physiology.

[48]  K. Kaibuchi,et al.  Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats , 2004, Circulation research.